TickerFacts.

Company research / JNJ

Johnson & Johnson (JNJ)

Build a valuation ↗↓ Download CSV

SEC name JOHNSON & JOHNSON · CIK 0000200406 · NYSE · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated NJ
  • Fiscal year ends around Jan 3

For the year ended 2025-12-28, Johnson & Johnson reported revenue of $94.19B. Revenue grew 6.0% from the prior annual period. Over the twelve months to 2026-09-27, revenue was $99.33B.

Key ratios (year ended 2025-12-28)

67.9%
Gross margin
28.5%
Net margin
32.9%
Return on year-end equity
6.0%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 10-Q (quarterly report) · 2026-10-21

Headquarters locality: New Brunswick · View on map

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-09-27 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-09-27		2025-12-282024-12-292023-12-312023-01-01, Fiscal 20222022-01-02, Fiscal 20212021-01-03, Fiscal 20202019-12-292018-12-302017-12-312017-01-01, Fiscal 2016
Revenue$99.33B$94.19B$88.82B$85.16B$79.99B$78.74B$82.58B$82.06B$81.58B$76.45B$71.89B
Cost of Revenue$32.22B$30.26B$27.47B$26.55B$24.60B$23.40B$28.43B$27.56B$27.09B$25.44B$21.79B
Gross Profit$67.11B$63.94B$61.35B$58.61B$55.39B$55.34B$54.16B$54.50B$54.49B$51.01B$50.10B
R&D Expense$16.08B$14.66B$17.23B$15.09B$14.13B$14.28B$12.16B$11.36B$10.78B$10.59B$9.14B
Depreciation & Amortization$8.09B$7.50B$7.34B$7.49B$6.97B$7.39B$7.23B$7.01B$6.93B$5.64B$3.75B
Net Income$16.09B$26.80B$14.07B$35.15B$17.94B$20.88B$14.71B$15.12B$15.30B$1.30B$16.54B
EPS (Diluted)n/a$11.03$5.79$13.72$6.73$7.81$5.51$5.63$5.61$0.47$5.93
Total Assets$197.43B$199.21B$180.10B$167.56B$187.38B$182.02B$174.89B$157.73B$152.95B$157.30B$141.21B
Total Liabilities$115.90B$117.67B$108.61B$98.78B$110.57B$108.00B$111.62B$98.26B$93.20B$97.14B$70.79B
Long-Term Debtn/a$41.44B$32.40B$27.35B$28.44B$32.12B$34.43Bn/an/an/an/a
Shareholders' Equity$81.53B$81.54B$71.49B$68.77B$76.80B$74.02B$63.28B$59.47B$59.75B$60.16B$70.42B
Cash & Equivalents$16.91B$19.71B$24.11B$21.86B$12.89B$14.49B$13.98B$17.30B$18.11B$17.82B$18.97B
Operating Cash Flow$26.16B$24.53B$24.27B$22.79B$21.19B$23.41B$23.54B$23.42B$22.20B$21.06B$18.77B
Capital Expenditures$5.57B$4.83B$4.42B$4.54B$4.01B$3.65B$3.35B$3.50B$3.67B$3.28B$3.23B
Free Cash Flow$20.59B$19.70B$19.84B$18.25B$17.18B$19.76B$20.19B$19.92B$18.53B$17.78B$15.54B
Share Repurchases$7.88B$5.95B$2.43B$5.05B$6.04B$3.46B$3.22B$6.75B$5.87B$6.36B$8.98B
Dividends Per Sharen/a$5.14$4.91$4.70$4.45$4.19$3.98$3.75$3.54$3.32$3.15
Weighted Average Diluted Sharesn/a2.43B2.43B2.56B2.66B2.67B2.67B2.68B2.73B2.75B2.79B
EPS (Basic)n/a$11.13$5.84$13.88$6.83$7.93$5.59$5.72$5.70$0.48$6.04

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView